Lista de obras - Eva Hellström-Lindberg - Dominio Público Uruguay

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial ⬇️

artículo científico publicado el 12 de abril de 2013

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome

artículo científico publicado en 2014

A pharmacodynamic study of 5-azacytidine in the P39 cell line

artículo científico publicado en 2006

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

artículo científico publicado en 2014

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts

artículo científico publicado en 2015

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

artículo científico publicado en 2011

Approach to anemia associated with myelodysplastic syndromes.

artículo científico publicado en 2003

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

artículo científico publicado en 2009

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

artículo científico publicado en 2013

Clinical and biological implications of driver mutations in myelodysplastic syndromes

artículo científico publicado en 2013

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

artículo científico publicado en 2017

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

artículo científico publicado en 2011

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

artículo científico publicado en 2011

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

artículo científico publicado en 2009

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease

artículo científico publicado en 2017

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

artículo científico publicado en 2011

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions ⬇️

artículo científico publicado en 2013

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

artículo científico publicado en 2017

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

artículo científico publicado en 2008

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

artículo científico publicado en 2013

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

artículo científico publicado en 2010

Erythropoiesis stimulating agents and other growth factors in low-risk MDS.

artículo científico

Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data

artículo científico publicado en 2017

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome

artículo científico publicado en 2016

H-Net, the European Network for Harmonization of Training in Hematology, and its policy ⬇️

artículo científico publicado el 9 de noviembre de 2012

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes

artículo científico publicado en 2008

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

artículo científico publicado en 2017

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

artículo científico publicado en 2007

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

artículo científico publicado en 2010

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

artículo científico publicado en 2010

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

artículo científico publicado en 2009

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy

artículo científico publicado en 2016

Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers

artículo científico publicado en 2009

New clues to the molecular pathogenesis of myelodysplastic syndromes

artículo científico publicado en 2010

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

artículo científico publicado en 2014

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality

artículo científico publicado en 2016

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion

artículo científico publicado en 2010

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

artículo científico publicado en 2016

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

artículo científico publicado en 2010

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome

artículo científico publicado en 2022

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

artículo científico publicado en 2012

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

artículo científico publicado en 2017

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

artículo científico publicado en 2013

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

artículo científico publicado en 2017

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)

artículo científico publicado en 2020

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

artículo científico publicado en 2009

Significance of JAK2 and TET2 mutations in myelodysplastic syndromes

artículo científico publicado en 2010

Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes

artículo científico publicado en 2008

Supportive care, growth factors, and new therapies in myelodysplastic syndromes

artículo científico publicado en 2008

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes

artículo científico publicado en 2017

The role of JAK2 mutations in RARS and other MDS.

artículo científico publicado en 2008

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts

artículo científico publicado en 2008

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

artículo científico publicado en 2012

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

artículo científico publicado en 2010

deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

artículo científico publicado en 2014

Eficacia de la azacitidina en comparación con los regímenes de atención convencionales en el tratamiento de los síndromes mielodisplásicos de mayor riesgo: un estudio de fase III, aleatorizado, abierto

artículo científico publicado en 2009

Lista de obras de Eva Hellström-Lindberg

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial ⬇️

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome

A pharmacodynamic study of 5-azacytidine in the P39 cell line

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

Approach to anemia associated with myelodysplastic syndromes.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions ⬇️

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

Erythropoiesis stimulating agents and other growth factors in low-risk MDS.

Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome

H-Net, the European Network for Harmonization of Training in Hematology, and its policy ⬇️

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy

Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers

New clues to the molecular pathogenesis of myelodysplastic syndromes

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

Significance of JAK2 and TET2 mutations in myelodysplastic syndromes

Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes

Supportive care, growth factors, and new therapies in myelodysplastic syndromes

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes

The role of JAK2 mutations in RARS and other MDS.

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Eficacia de la azacitidina en comparación con los regímenes de atención convencionales en el tratamiento de los síndromes mielodisplásicos de mayor riesgo: un estudio de fase III, aleatorizado, abierto